Log in

NASDAQ:SSRX - 3SBio Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume149,084 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
3SBio Inc is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:SSRX
CUSIPN/A
Phone+86-24-25811820

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SSRX News and Ratings via Email

Sign-up to receive the latest news and ratings for SSRX and its competitors with MarketBeat's FREE daily newsletter.


3SBio (NASDAQ:SSRX) Frequently Asked Questions

What is 3SBio's stock symbol?

3SBio trades on the NASDAQ under the ticker symbol "SSRX."

How were 3SBio's earnings last quarter?

3SBio Inc (NASDAQ:SSRX) announced its quarterly earnings data on Monday, March, 18th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.14 by $0.02. The biotechnology company had revenue of $26.30 million for the quarter, compared to analyst estimates of $25.63 million. View 3SBio's Earnings History.

Has 3SBio been receiving favorable news coverage?

Press coverage about SSRX stock has been trending very negative on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. 3SBio earned a news impact score of -3.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for 3SBio.

What other stocks do shareholders of 3SBio own?

Who are 3SBio's key executives?

3SBio's management team includes the folowing people:
  • Jing Lou, Executive Chairman of the Board, Chief Executive Officer (Age 54)
  • Bo Tan, Chief Financial Officer, Executive Vice President, Executive Director (Age 44)
  • Fei You, Director - Finance (Age 38)
  • Weihonghas Xiao, Chief Operating Officer (Age 48)
  • Dongmei Su, Senior Vice President, Executive Director (Age 46)
  • Zhenping Zhu MD. Ph.D., Chief Scientific Officer, President - Research & Development (Age 52)
  • Bin Huang, Vice President, Executive Director (Age 56)
  • Xin Ma, Vice President - Human Resources (Age 51)
  • Yongfu Chen, Vice President (Age 60)
  • Kevin Liu, Vice President (Age 47)

What is 3SBio's official website?

The official website for 3SBio is http://www.3sbio.com/.

How can I contact 3SBio?

3SBio's mailing address is No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone, SHENYANG, LIA 110027, China. The biotechnology company can be reached via phone at +86-24-25811820.


MarketBeat Community Rating for 3SBio (NASDAQ SSRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about 3SBio and other stocks. Vote "Outperform" if you believe SSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: VIX - Volatility Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel